Welcome to our dedicated page for Neoleukin Therapeutics news (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on Neoleukin Therapeutics stock.
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical innovator developing next-generation immunotherapies through advanced protein design. This hub provides essential updates on corporate developments and research milestones for investors tracking this Nasdaq-listed company.
Access authoritative reports on key financial actions including the 2023 reverse stock split and operational restructuring designed to optimize capital allocation. Stay informed about strategic initiatives like the proposed merger and its implications for shareholder value.
Our curated news collection features verified updates on:
• Therapeutic pipeline advancements
• Corporate governance decisions
• Financial strategy implementations
• Partnership and merger developments
For direct inquiries, consult Neoleukin's official website or contact investor relations at investors@neoleukin.com. Bookmark this page for real-time updates on NLTX's progress in redefining immunotherapy treatments.
Neoleukin Therapeutics (NASDAQ:NLTX) reported Q2 2021 results highlighting key progress in its clinical pipeline. The lead candidate, NL-201, is undergoing a Phase 1 trial for advanced solid tumors, with interim data expected in 2022. The company reported a cash position of $164.2 million, down from $192.6 million at year-end 2020, sufficient to fund operations into 2023. R&D expenses surged to $9.8 million, reflecting increased trial activities. The net loss for Q2 was $15.1 million, up from $9.7 million in Q2 2020. Neoleukin is prioritizing NL-201's development despite some pandemic-related delays.
Neoleukin Therapeutics (NASDAQ:NLTX) announced CEO Jonathan Drachman will join a virtual fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 8:00 a.m. ET. The event will feature a live audio webcast, accessible through the investor section of Neoleukin's website, along with an archived replay available for 30 days post-event. Neoleukin specializes in immunotherapies for cancer and autoimmune diseases through its innovative de novo protein design technology, with its lead candidate being NL-201, a combined IL-2 and IL-15 agonist.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 a.m. ET. The event will include a live audio webcast available on Neoleukin's investor website, with an archived replay accessible for 30 days post-event. Neoleukin specializes in designing de novo protein therapeutics aimed at treating cancer, inflammation, and autoimmunity. Its lead candidate, NL-201, is an IL-2 and IL-15 agonist, promising enhanced efficacy and tolerability.
Neoleukin Therapeutics (NASDAQ:NLTX) has initiated a Phase 1 trial for NL-201, with the first patient dosed in May 2021. The trial aims to evaluate NL-201's safety and efficacy in advanced solid tumors. Neoleukin reported a cash position of $178.4 million as of March 31, 2021, which is expected to fund operations into 2023. The R&D expenses increased to $9.7 million, and the net loss for Q1 2021 was $14.9 million. Additionally, Dr. Priti Patel was appointed as Chief Medical Officer, enhancing the leadership team.
Neoleukin Therapeutics (NASDAQ:NLTX) has initiated a Phase 1 clinical trial for NL-201, targeting patients with advanced solid tumors. The trial, which has commenced with the first patient dosed in Australia, aims to enroll up to 120 patients to evaluate the safety and efficacy of NL-201, a novel protein designed to mimic IL-2 and IL-15. Key objectives include assessing safety, pharmacokinetics, and potential anti-tumor activity. Neoleukin anticipates expanding the study to specific cohorts, including those with renal cell carcinoma and melanoma.
Neoleukin Therapeutics, a biopharmaceutical company listed on NASDAQ as NLTX, will have its CEO, Jonathan Drachman, participate in a fireside chat at the BofA Securities 2021 Healthcare Conference on May 12, 2021, at 10:15 a.m. ET. A live audio webcast will be available on Neoleukin's investor website, with an archived replay accessible for at least 30 days post-event. Neoleukin focuses on creating innovative immunotherapies through de novo protein design technology, with its lead candidate, NL-201, aimed at improving tolerability and effectiveness in therapeutic applications.
Neoleukin Therapeutics (NASDAQ:NLTX) appointed Dr. Priti Patel as Chief Medical Officer. Bringing extensive experience from AstraZeneca, where she led clinical development in hematology, Dr. Patel's background includes overseeing over 6 Phase 3 and 20 Phase 1/2 studies. CEO Jonathan Drachman highlighted her expertise as vital for initiating the clinical trial of NL-201 and shaping future strategies. Neoleukin focuses on innovative therapies utilizing de novo protein design technology, with NL-201 being a lead candidate aimed at enhancing cancer treatment.
Neoleukin Therapeutics (NASDAQ: NLTX) has announced the lifting of a clinical hold by the FDA for its Phase 1 trial of NL-201, an immunotherapeutic candidate. Previously, the FDA required a new assay to ensure accurate dosing of NL-201. The Phase 1 study aims to evaluate NL-201's safety and preliminary efficacy in treating advanced solid tumors in up to 120 patients across North America and Australia. NL-201 functions as a receptor agonist for IL-2 and IL-15, designed to enhance the proliferation of cancer-fighting CD8 T and NK cells while reducing regulatory T cell interference.
Neoleukin Therapeutics (NASDAQ:NLTX) provided a corporate update and financial results for the year ended December 31, 2020. The company anticipates initiating its NL-201 Phase 1 trial in Australia in the first half of 2021. Cash and cash equivalents stand at $192.6 million, expected to fund operations into 2023. Research and development expenses increased to $24.3 million, reflecting heightened IND-enabling activities. Neoleukin reported a net loss of $33.3 million for 2020, a reduction from $69.4 million in 2019. The company plans to host a conference call on March 25, 2021.
Neoleukin Therapeutics (NASDAQ:NLTX) will report its full year 2020 financial results on March 25, 2021, after market close. A conference call and audio webcast will follow at 1:30 PM Pacific / 4:30 PM Eastern to discuss these results and provide updates on the company’s developments, particularly regarding its lead product candidate NL-201, an immunotherapy aimed at improving tolerability and activity. Neoleukin utilizes advanced computational methods for its de novo protein therapeutics, addressing cancer and autoimmune diseases.
